Advocates

Analytical Methods

Auto-immune Diseases

Breast Cancer

COVID-19

Cannabinoids

Cannabis Perspectives

Cannabis Strains

Caregivers

Chromatography Techniques

Chronic Pain

Consensus Methods

Contaminants

Cultivation

Doctors

Edibles

Extraction

GC-MS

Gas Chromatography (GC)

Government

Growers and Growing

HPLC and UHPLC

Healthcare

Hemp

ICP-MS

International Updates

LC-MS

Laboratory Accreditation

Laboratory Best Practices

Legal Issues

Manufacturing

Mass Spectrometry

Medical Cannabis

Medical Marijuana (MMJ)

Mental Health

Noid Factoid

Nurses

PTSD

Patients

Pediatric Cancer

Pesticides

Potency

Processing

Psychedelics

Q&A with ASA: Meet the Chapters

Quality Control and Quality Assurance

Regulations and Regulatory Issues

Research

Sample Preparation

Seizure Disorders

Spectroscopy Techniques

Terpenes

Tetrahydrocannabinol (THC)

Veterans

News

Resources

Editorial Videos

Sponsor Videos

e-Learning Tools

Events

Products

Blogs

Columns

Publications

Webcasts

App Notes

Podcasts

Editorial Podcasts

Podcast Series

Subscribe

Cannabis Science and Technology provides expert insights on testing, cultivation, extraction, and more in the cannabis industry.

About Us

Advertise

Contact Us

Editorial Board

Editorial Information

Terms of Use

Privacy Policy

Do not sell my Information

Cannabis Science and Technology - Cannabis Industry News, Insights

Facebook

Twitter

Instagram

LinkedIn

Spotlight

Call for Papers 

THC vs THCA

Noid Factoid 

Topics

Cannabidiol (CBD)

Quality Control and Quality Assurance (QA and QC)

1rem

Topic

Here, we bring you our top five recent articles covering veterans and medical cannabis, cannabis legalized by the Omaha tribe, low THC extracts for Rett syndrome, ICE raids at a cannabis farm, and our newest Noid Factoid.

Best of the Week: July 11 – July 17, 2025

The New Jersey Cannabis Regulatory Commission recently approved four on-site cannabis consumption areas, the first locations for the state.

First On-Site Cannabis Consumption Areas Approved By New Jersey Cannabis Regulatory Commission

The Omaha Tribe of Nebraska made history by becoming the first fully legal and regulated cannabis system in the state for both recreational and medical cannabis.

Adult-Use and Medical Cannabis Legalized by Omaha Tribe of Nebraska

The “Big, Beautiful Bill” signed recently into law by President Donald Trump, includes an amendment that may end the medical cannabis ban in the VA which has prevented doctors from recommending the plant to their patients.

House Budget Bill Amendment Could End Veterans Affairs Medical Cannabis Ban

ICE federal agents raided cannabis nurseries in Southern California, sparking protests from migrant-rights activists.

Southern California ICE Raids Targeting Cannabis Nurseries Trigger Protests

Leading the new Compliance Track for Cannabis Science Conference Spring 2024 is Kim Stuck, founder and CEO of Allay Consulting, a compliance strategy and services provider serving the hemp and cannabis industries nationwide. Stuck is also a regular writer for 

. The conference is May 7–9, 2024, in Kansas City, Missouri, and also features the Analytical Track, Medical Track, and Cultivation Track.

Get a sneak peek into the Compliance Track, read the interview transcription below, and 

reserve your spot for Cannabis Science Conference Spring 2024

As the Chair for the new Compliance Track, Kim Stuck discusses what topics we can look forward to at the upcoming conference.

Cannabis Science Conference Spring 2024: Interview with Compliance Track Program Chair Kim Stuck

Read some of the Compliance Track focuses in the transcript below:

What are some new topics in cannabis compliance?

: The biggest topic that everybody is discussing is the Schedule 3 change. That is going to be the topic of discussion probably at the conference as well the whole time, because we're just not quite sure where they're going to go, what they're going to do, which is fine. I feel like that's been the way that we've been functioning the entire time we've been a part of the industry. But, like I said, I was just in Spain speaking about the Schedule 3, and how it can affect everything. There's a lot of different ways that can go, I think that people have a lot of fear about it, they think that they're going to make it be a pharmaceutical and all these different things that I do not think are going to happen. I don't think people need to be that worried about the Schedule 3 change—I think it'll actually be a really good thing. I think there'll be a lot of discussions on how they might be regulating it at that point. Obviously the FDA [Food and Drug Administration] will get involved, GMP [Good Manufacturing Practice] certification is on the table to be required, ASTM standards are on the table to be required, and OSHA [Occupational Safety and Health Administration] is going to be a part of it now. So there's a lot of things to take into consideration. But I think that that's going to be a huge topic. And I think we do have a couple of panels even speaking about that. So it should be a good discussion, for sure.

What topics are being covered in the compliance track?

: A lot of regulators are going to be speaking, so we have quite a few people who have regulatory backgrounds that are going to be a part of the track, which I think is always really good. Getting their perspectives, knowing what are the top five things that they're seeing that are issues, or understanding how compliance is working in different states. So if we have a regulator that's from Colorado, versus a regulator from California, their perspective is going to be very different. And so we really tried to diversify and do a lot of compliance from different viewpoints, if you will, if that makes sense. So I think they're going to touch on a lot of different topics. Compliance is a very broad term that covers a whole lot of different things. But I think that having a lot of regulator focus, and government-focused speakers was my goal this time around.

What are you most looking forward to learning at the conference?

: Just more of the medical aspects. I feel like every year there's more and more data on medical stuff. And I recently had some health struggles that cannabis helped me through this last year. So just learning more about that is really what I'm looking forward to, especially with the new cannabinoids that are being discovered. The ways that they're using different cannabinoids in different ways. It's really exciting. Obviously, the medical side of everything is very exciting. So I'm really hoping to just learn more of that side when I'm not in the compliance track. I'm probably going to be on the other side, especially with data and testing and all that fun stuff. So I'm excited to learn more. I love these conferences because you do always walk away learning so much more than you walked in with.

Videos

As the Chair for the new Compliance Track, Kim Stuck discusses what topics we can look forward to at the upcoming conference. 

In this interview, consultant Kim Stuck shares highlights from her presentation, insider knowledge in the industry, plus how her profession intersects with research she encountered at the conference. During the conference she moderated the analytical track panel, “Quality Assurance and Safety in Cannabis, Psilocybin, and Hemp.”

 blog, Stuck on Compliance? Read her latest updates in the regulatory sector 

Onsite interview with Kim Stuck, founder and CEO of Allay Consulting, as she shares her unique insights and experiences in the industry

Cannabis Science Conference Live: Kim Stuck

Filmed onsite at Cannabis Science Conference Spring 2023, Kim Stuck, founder and CEO of Allay Consulting, shares her unique insights and experiences in the industry.

Regulations and Regulatory Issues

Latest News